Free Trial

Artiva Biotherapeutics (ARTV) Competitors

Artiva Biotherapeutics logo
$1.98 -0.02 (-1.00%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$1.90 -0.08 (-4.04%)
As of 08:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ARTV vs. OCGN, ACTU, MDWD, NVCT, ANNX, IPHA, CRGX, VYGR, YMAB, and IVA

Should you be buying Artiva Biotherapeutics stock or one of its competitors? The main competitors of Artiva Biotherapeutics include Ocugen (OCGN), Actuate Therapeutics (ACTU), MediWound (MDWD), Nuvectis Pharma (NVCT), Annexon (ANNX), Innate Pharma (IPHA), CARGO Therapeutics (CRGX), Voyager Therapeutics (VYGR), Y-mAbs Therapeutics (YMAB), and Inventiva (IVA). These companies are all part of the "pharmaceutical products" industry.

Artiva Biotherapeutics vs.

Artiva Biotherapeutics (NASDAQ:ARTV) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, risk, dividends, earnings and valuation.

Artiva Biotherapeutics has a net margin of 0.00% compared to Ocugen's net margin of -532.51%. Artiva Biotherapeutics' return on equity of 0.00% beat Ocugen's return on equity.

Company Net Margins Return on Equity Return on Assets
Artiva BiotherapeuticsN/A N/A N/A
Ocugen -532.51%-154.75%-90.79%

Artiva Biotherapeutics currently has a consensus target price of $19.40, indicating a potential upside of 879.80%. Ocugen has a consensus target price of $6.00, indicating a potential upside of 556.53%. Given Artiva Biotherapeutics' higher probable upside, research analysts clearly believe Artiva Biotherapeutics is more favorable than Ocugen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Artiva Biotherapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Ocugen
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

10.3% of Ocugen shares are owned by institutional investors. 21.4% of Artiva Biotherapeutics shares are owned by insiders. Comparatively, 4.4% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Artiva Biotherapeutics has higher earnings, but lower revenue than Ocugen.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Artiva Biotherapeutics$251K192.19N/AN/AN/A
Ocugen$4.52M59.02-$63.08M-$0.19-4.81

In the previous week, Artiva Biotherapeutics had 3 more articles in the media than Ocugen. MarketBeat recorded 4 mentions for Artiva Biotherapeutics and 1 mentions for Ocugen. Ocugen's average media sentiment score of 1.26 beat Artiva Biotherapeutics' score of -0.21 indicating that Ocugen is being referred to more favorably in the news media.

Company Overall Sentiment
Artiva Biotherapeutics Neutral
Ocugen Positive

Ocugen received 100 more outperform votes than Artiva Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Artiva Biotherapeutics an outperform vote while only 71.43% of users gave Ocugen an outperform vote.

CompanyUnderperformOutperform
Artiva BiotherapeuticsOutperform Votes
15
100.00%
Underperform Votes
No Votes
OcugenOutperform Votes
115
71.43%
Underperform Votes
46
28.57%

Summary

Artiva Biotherapeutics beats Ocugen on 9 of the 13 factors compared between the two stocks.

Get Artiva Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARTV vs. The Competition

MetricArtiva BiotherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$48.24M$2.93B$5.33B$8.39B
Dividend YieldN/A1.63%5.21%4.10%
P/E RatioN/A31.1826.7719.70
Price / Sales192.19398.78393.27122.35
Price / CashN/A168.6838.2534.62
Price / BookN/A3.236.774.50
Net IncomeN/A-$72.35M$3.23B$248.22M
7 Day Performance-2.46%2.49%0.43%-0.80%
1 Month Performance-19.18%2.45%9.07%11.52%
1 Year PerformanceN/A-24.98%18.57%8.99%

Artiva Biotherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARTV
Artiva Biotherapeutics
1.69 of 5 stars
$1.98
-1.0%
$19.40
+879.8%
N/A$48.24M$251,000.000.0081
OCGN
Ocugen
1.186 of 5 stars
$0.70
+4.5%
$6.00
+757.1%
-46.9%$204.42M$4.06M-3.8980Positive News
ACTU
Actuate Therapeutics
N/A$10.45
+1.0%
$20.50
+96.2%
N/A$204.11MN/A0.0010News Coverage
MDWD
MediWound
1.5446 of 5 stars
$18.65
+6.4%
$29.75
+59.5%
+15.5%$201.57M$20.22M-6.4380News Coverage
Earnings Report
Analyst Forecast
NVCT
Nuvectis Pharma
2.1937 of 5 stars
$8.39
-6.7%
$17.00
+102.6%
+49.2%$198.30MN/A-7.238
ANNX
Annexon
1.857 of 5 stars
$1.77
+10.6%
$18.67
+954.6%
-57.8%$194.19MN/A-1.6960
IPHA
Innate Pharma
1.918 of 5 stars
$2.28
-6.8%
$11.00
+383.5%
-27.3%$190.71M$12.62M0.00220Gap Down
CRGX
CARGO Therapeutics
2.1717 of 5 stars
$4.07
+1.2%
$15.00
+268.6%
-80.5%$187.67MN/A-0.96116Gap Up
VYGR
Voyager Therapeutics
4.665 of 5 stars
$3.35
+5.7%
$13.97
+316.9%
-64.0%$185.30M$80.00M4.72100
YMAB
Y-mAbs Therapeutics
3.4392 of 5 stars
$4.07
+4.6%
$17.40
+327.5%
-67.9%$184.28M$87.69M-7.54150Analyst Revision
IVA
Inventiva
2.0023 of 5 stars
$3.51
-3.0%
$10.40
+196.3%
-15.9%$184.19M$9.20M0.00100News Coverage
Gap Down

Related Companies and Tools


This page (NASDAQ:ARTV) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners